Breast Cancer, Osteoporosis
Conditions
Brief summary
Chemotherapy can damage bone marrow and therefore impair the production of white blood cells, platelets and red blood cells with the resulting anemia and osteoporosis.
Detailed description
Purposes of this study were: 1. To determine the therapeutic efficacy of the whole-body vibration (WBV) in improving osteoporosis in breast cancer patients after receiving chemotherapy within 3-6 months. 2. To determine the therapeutic efficacy of the weight bearing exercise in improving osteoporosis in breast cancer patients after receiving chemotherapy within 3-6 months. 3. To gain knowledge about the whole-body vibration (WBV) and the weight bearing exercise in improving osteoporosis in breast cancer patients after receiving chemotherapy within 3-6 months. 4. To share in designing an ideal protocol for the treatment of the osteoporosis in breast cancer patients after receiving chemotherapy within 3-6 months.
Interventions
Whole body vibration apparatus (model Power plate -my5tm, made in United States) with frequency 30 - 40 Hz was used for the whole body vibration program by reciprocating vertical displacements on the left and right side of a fulcrum.
Electronic treadmill Kettler- marathon model No 7899-800, made in Germany (as form of weight bearing exercises), which was adjusted to the subject's comfortable walking speed. Generally, during the treadmill training, its speed and inclination are electronically adjusted, and it is also provided with a control panel to display the exercise parameters. It allows for the comfortable running without joint or back pains through a perfect combination between aluminium-pertinax running deck, shock absorbers and overall shock-damping design.
DRUGvitamin D supplements and calcium
vitamin D supplements and calcium
Sponsors
Cairo University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
35 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Breast cancer patients after receiving chemotherapy within 3-6 months and complaining from osteoporosis. * Their age ranges from 35-55 years old. * All patients will have the same medical and nursing care. * All the patients will receive a good explanation of treatment and measurement device. * They are neurologically free.
Exclusion criteria
Patients will be excluded from this study for any of the following causes: * Uncooperative patients. * Instability of patient's medical condition. * Association of another medical problem. * Patients who have diabetes. * Patients who have history of medical chronic relevant diseases. * Patients who have acute or chronic hepatitis. * Patients who have pacemaker. * Patients who have genitourinary infections.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessing the change in bone mineral density | at baseline and after 2 months of intervention | By using DEXA (dual-energy X-ray absorptiometry): Dual-energy X-ray absorptiometry (DEXA) is a clinically proven method of measuring bone mineral density (BMD) in the lumbar spine, proximal femur, forearm, and whole body. It is used primarily in the diagnosis and management of osteoporosis and other disease states characterized by abnormal BMD, as well as to monitor response to therapy for these conditions . |
Countries
Egypt
Outcome results
None listed